ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 21. Okt. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
VAN DER WAL ERIK [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-10-21, Last update posted on www.tib.eu: 2023-05-28, Last updated: 2023-06-06 |
|---|
| Patentnummer: |
US2021322526 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA014148102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA014148102 | ||
| 003 | DE-627 | ||
| 005 | 20230607091647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA014148102 | ||
| 035 | |a (EPA)US2021322526 | ||
| 035 | |a (EPA)55346165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a VAN DER WAL ERIK |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-10-21, Last update posted on www.tib.eu: 2023-05-28, Last updated: 2023-06-06 | ||
| 520 | |a The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BERGSMA ATZE JACOBUS |4 aut | |
| 700 | 0 | |a PIJNAPPEL WILHELMUS WENCESLAUS MATTHIAS |4 aut | |
| 700 | 0 | |a VAN DER PLOEG ANTJE TJITSKE |4 aut | |
| 700 | 0 | |a REUSER ARNOLDUS |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 21. Okt. |
| 773 | 1 | 8 | |g year:2021 |g day:21 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/55346165/publication/US2021322526A1?q=US2021322526 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 21 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 21 |c 10 | ||